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Abstract
Summary This retrospective database study assessed 2-year per-
sistence with bisphosphonates or denosumab in a large German
cohort of women with a first-time prescription for osteoporosis
treatment. Compared with intravenous or oral bisphosphonates,
2-year persistence was 1.5–2 times higher and risk of discontin-
uation was significantly lower (P<0.0001) with denosumab.
Introduction Persistence with osteoporosis therapies is critical
for fracture risk reduction. Detailed data on long-term persistence
(≥2 years) with bisphosphonates and denosumab are sparse.
Methods From the German IMS® database, we included
women aged 40 years or older with a first-time prescrip-
tion for bisphosphonates or denosumab between
July 2010 and August 2014; patients were followed up
until December 2014. The main outcome was treatment
discontinuation, with a 60-day permissible gap between
filled prescriptions. Two-year persistence was estimated
using Kaplan–Meier survival curves, with treatment dis-
continuation as the failure event. Denosumab was com-
pared with intravenous (i.v.) and oral bisphosphonates
separately. Cox proportional hazard ratios (HRs) for the
2-year risk of discontinuation were calculated, with ad-
justment for age, physician specialty, health insurance
status, and previous medication use.
Results Two-year persistence with denosumab was signif-
icantly higher than with i.v. or oral bisphosphonates
(39.8 % [n= 21,154] vs 20.9 % [i.v. ibandronate; n= 20,
472] and 24.8 % [i.v. zoledronic acid; n= 3966] and 16.7–
17.5 % [oral bisphosphonates; n= 114,401]; all P< 0.001).
Patients receiving i.v. ibandronate, i.v. zoledronic acid, or
oral bisphosphonates had a significantly increased risk of
treatment discontinuation than did those receiving
denosumab (HR= 1.65, 1.28, and 1.96–2.02, respectively;
all P< 0.0001).
Conclusions Two-year persistence with denosumab was
1.5–2 times higher than with i.v. or oral bisphosphonates,
and risk of discontinuation was significantly lower with
denosumab than with bisphosphonates. A more detailed
understanding of factors affecting medication-taking be-
havior may improve persistence and thereby reduce rates
of fracture.
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Introduction
Osteoporosis is recognized worldwide as an important health
condition because of its high prevalence and detrimental con-
sequences, such as increased risk of fractures. It is character-
ized by extensive loss of bone mass due to structural deterio-
ration of bone, which leads to increasing frailty [1, 2]. The
most recent report on the prevalence of osteoporosis among
1.7 million individuals registered on a health insurance data-
base in Germany found that the condition affects approximate-
ly 14 % of the overall population above the age of 50 years
and approximately 24 % of women in this age group [3].
Several osteoporosis treatments are available that have
been found to be effective in randomized controlled trials
(RCTs). Bisphosphonates, which were introduced as an
antiresorptive therapy in the mid-1990s, suppress osteoclast
activity, thereby reducing bone turnover and increasing bone
mineral density. In turn, this significantly reduces fracture rate
[4]. However, depending on concomitant disease and medica-
tions, oral bisphosphonates may be associated with poor ab-
sorption and gastrointestinal adverse events [5]. Intravenous
(i.v.) bisphosphonates became available a decade later, offer-
ing a new mode of administration. More recently, subcutane-
ous (s.c.) denosumab was approved for the treatment of men
and postmenopausal women at increased risk of fracture [6].
Denosumab is a fully human monoclonal antibody with affin-
ity and specificity for RANK ligand (RANKL) [7], a primary
mediator of osteoclast activity and differentiation [8].
The chronic nature of osteoporosis means that long-term
treatment is required. This can, however, lead to poor persis-
tence and compliance with medication, both of which increase
fracture risk [9–14]. In two large retrospective cohort analyses
on compliance and persistence and the associated risk of frac-
tures, which included more than 4000 women receiving vari-
ous oral bisphosphonates (GRAND) [9] and 296,300
Hungarian women receiving osteoporosis therapies adminis-
tered orally or parenterally [15], 2-year persistence with treat-
ment was only 12.9 and 16 %, respectively. These studies
showed that both compliance and persistence with treatment
had a significant impact on fracture risk; hence, the persistence
rates reported in these studies appear inadequate. Similar anal-
yses of persistence with i.v. bisphosphonates in Germany
showed moderate 12-month persistence rates of 65.6 % for
zoledronic acid 5 mg i.v. (administered every 12 months)
and 56.6 % for ibandronate 3 mg i.v. (administered every
3 months) [16], and the literature analysis performed as part
of the Swedish Adherence Register Analysis (SARA) study
found that 2-year persistence with oral bisphosphonates re-
ported in studies from around the world ranged from 16 to
46 % [17].
In contrast to these findings, in a prospective, non-
interventional study of women with postmenopausal osteopo-
rosis [18] conducted in North America, 12-month persistence
with 6-monthly denosumab was 82 %. Interestingly, patients
with the highest persistence rates were those with exposure to
other osteoporosis treatments before enrollment (83 % for
those with previous exposure vs 74 % for those without),
which may indicate that switching from other osteoporosis
treatments (e.g., bisphosphonates) to denosumab can improve
treatment persistence [18]. Similar 12-month persistence rates
with denosumab of 70–95.5 % were reported in a European
observational study of 1500 women with postmenopausal os-
teoporosis, the SARA study of 2315 women with postmeno-
pausal osteoporosis, a retrospective German cohort analysis of
6159 denosumab-naïve women with osteoporosis, and the
Hungarian study noted above [15, 17, 19, 20]. Furthermore,
the improvement in persistence following a medication switch
may be greater when patients switch to denosumab than to
another bisphosphonate: a pooled analysis of data from two
international, randomized, open-label studies found that wom-
en with poor adherence to dai ly or weekly oral
bisphosphonates reported better treatment satisfaction when
switching to denosumab than when switching to monthly oral
bisphosphonates [21]. These findings are very promising;
however, data on persistence rates for i.v. bisphosphonates
and denosumab over a 2-year period are sparse. It is also still
not clear which factors are associated with poor persistence.
The aim of this study was to evaluate long-term persistence
with different osteoporosis treatments in a large sample of
women receiving oral or i.v. bisphosphonates, or s.c.
denosumab in a real-world setting in Germany, and to identify




This study used the IMS® Longitudinal Rx (LRx) database,
which includes data from pharmacy centers nationwide and is
used to process prescription data for all German patients with-
in statutory health insurance programs for reimbursement pur-
poses. Data entries comprise patient-specific information,
such as anonymized identification number, age, sex, insurance
company, and area of residence, as well as prescription infor-
mation, including the prescriber’s anonymized identification
number, prescription date, and pack size. The IMS LRx data-
base holds details of about 60 % of prescriptions issued in
Germany [22].
Study population
Women were included who had received a first-time prescrip-
tion for bisphosphonates (oral or i.v.) or denosumab (s.c. once
every 6 months) between July 2010 and a cutoff date of
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August 2013 for i.v. zoledronic acid once yearly, February
2014 for denosumab and oral bisphosphonates (alendronate
70 mg or risedronate 35 mg once weekly, ibandronate 150 mg
once monthly), or May 2014 for i.v. ibandronate once every
3 months. These follow-up dates were determined according
to drug administration frequency: the minimum follow-up pe-
riod was 16 months for zoledronic acid, 10 months for
denosumab, and 7 months for i.v. ibandronate. The date of
first prescription was defined as the index event, with
follow-up until December 2014 at the latest.
Further inclusion criteria were age 40 years or older at the
index event and the availability of data for at least 365 days
before the index date (necessary for valid identification of
treatment initiation).
Patients with a history of any prescription for antineoplastic
agents (Anatomical Therapeutic Chemical [ATC] class: L1),
cytostatic hormones (ATC class: L2), or any oncological treat-
ment documented within the 12-month period preceding the
index date were excluded.
Study outcomes
The main outcome was treatment discontinuation in the
2 years after the index date. Treatment discontinuation was
defined as a gap of more than 60 days without filling a new
prescription after the expected refill date during the observa-
tion period. Patients restarting their initial treatment or starting
another drug after a gap (Bgrace period^) of 60 days had
elapsed were classified as non-persistent, as were those who
discontinued their initial therapy and received no further treat-
ment. Patients who discontinued their original therapy and
started another drug within 60 days were included in the drug
cohort for which they maintained the longest duration of per-
sistence. Sensitivity analyses were performed with grace pe-
riods of 30, 90, and 120 days. Persistence was calculated using
the discontinuation data.
A longitudinal dataset of medication supply was built
for each patient, and non-persistence with each treat-
ment (denosumab, i.v. ibandronate, i.v. zoledronic acid,
oral alendronate, oral ibandronate, and oral risedronate)
was calculated. To build these longitudinal databases,
the number of days of drug supply was calculated from
quantity and dosage information associated with each
prescription record. All patients were followed up for
a minimum of the respective number of days of drug
supply plus 60 days and a maximum of up to 2 years
f r om t h e i r i n d e x d a t e , t o i d e n t i f y t h e r a p y
discontinuation.
Covariates
Previous treatments (prescriptions in the 12-month period be-
fore the index date) were categorized based on ATC
classifications and included calcium (ATC class: A12A), vita-
min D (ATC class: A11C2 or A11C3), hormone therapy (ATC
class: G03), and pain medication (ATC class: N02 or M01A).
Previous treatment also included oral bisphosphonates (ATC
class: M05B3); this particular category was included as a co-
variate in the analyses of i.v. bisphosphonates and denosumab.
Demographic data included age, health insurance type (gen-
eral regional funds [AOKs, Barmer GEK, TK, DAK],
company-based funds [BKKs], guild-based funds [IKKs] or
other funds), and specialty of the physician who initiated bis-
phosphonate therapy (orthopedic surgeon, internist, or other).
Statistical analysis
Kaplan–Meier survival curves were used to estimate 2-year
persistence rates, with treatment discontinuation as the failure
event. Two comparisons were made: denosumab versus i.v.
bisphosphonates and denosumab versus oral bisphosphonates.
The bisphosphonate data were pooled for each of these com-
parisons. Patients were censored at the time they were lost to
follow-up or when they discontinued treatment, whichever
occurred first. Covariates associated with treatment discontin-
uation were assessed using a Cox proportional hazards regres-
sion model, with a stepwise selection procedure and an entry
criterion of P=0.1 used to determine the final model. Cox
regression analyses were performed separately for compari-
sons of denosumab with i.v. bisphosphonates and denosumab
with oral bisphosphonates. Hazard ratios (HRs) for the 2-year
risk of therapy discontinuation were adjusted for age, physi-
cian specialty, health insurance status of the patient, and pre-
vious medication use.
The proportional hazards assumption was assessed and up-
held for all analyses. Two-sided tests were used, and a P value
of 0.05 was considered statistically significant. All analyses
were carried out using SAS 9.3 (SAS Institute, Cary, NC,
USA).
Results
Characteristics of study patients
Our analysis included 21,154 women treated with
denosumab, 20,472 receiving i.v. ibandronate, 3966 receiving
i.v. zoledronic acid, 90,077 receiving oral alendronate, 6235
receiving oral ibandronate, and 18,089 receiving oral
risedronate.
Baseline patient characteristics are summarized by
treatment in Tables 1 and 2. Patients treated with
denosumab were significantly older than those treated
with oral or i.v. bisphosphonates (both P < 0.001)
(Tables 1 and 2). Additionally, compared with patients
receiving i.v. or oral bisphosphonates, patients receiving
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denosumab were more likely to be treated by orthopedic
surgeons and were less likely to be treated by internists
(both P < 0.001). A significantly higher proportion of
pa t i en t s r e ce iv ing denosumab had used o ra l
bisphosphonates, calcium, vitamin D, and hormone ther-
apy in the 12 months before the index date than had
individuals in the oral and i.v. bisphosphonate groups
(both P < 0.001) (Tables 1 and 2). More than half
(52.4 %) of patients in the denosumab group had re-
ceived oral bisphosphonates at any time before initiating
denosumab, and 16.9 % had previously received an i.v.
bisphosphonate (data not shown).
Kaplan–Meier survival analyses
At 12 months, persistence with therapy was higher in the
denosumab group than in the i.v. ibandronate or i.v. zoledronic
acid groups (55.9 vs 42.9 and 33.8%, respectively). At 2 years
of follow-up, persistence with denosumab remained higher
than in the i.v. ibandronate or i.v. zoledronic acid groups
(39.8 vs 24.8 and 20.9 %; Table 3) A comparison of
denosumab with the pooled i.v. bisphosphonate data showed
that the difference in persistence was highly significant
(P<0.001; Fig. 1a). Persistence was also found to be higher
with denosumab than with i.v. bisphosphonates in the sensi-
tivity analyses, which used grace periods of 30, 90, and
120 days (Table 3).
At 12 months, persistence with denosumab was also
higher than with oral bisphosphonates (55.9 vs approxi-
mately 30 %), with sensitivity analyses using grace pe-
riods of 30, 90, and 120 days showing similar results
(Table 3). At 2 years of follow-up, the differences in
persistence were maintained, with a higher proportion of
persistent patients in the denosumab group than in the oral
bisphosphonate groups (39.8 vs 16.7–17.5 %). A compar-
ison of denosumab with the pooled oral bisphosphonate
data showed that this difference was highly significant
(P<0.001; Fig. 1b). The difference in persistence between
Table 1 Baseline characteristics










Age ≤60 years, % 7.1 8.1 11.9 <0.001
Age 61–70 years, % 18.9 20.2 21.4 <0.001
Age >70 years, % 74.1 71.7 66.7 <0.001
Specialty of doctor initiating therapy, %
Orthopedic surgeon 59.9 51.5 51.4 <0.001
Internist 33.5 42.8 37.4 <0.001
Other 6.5 5.7 11.1 <0.001
Health insurance company, %
AOK 41.6 43.5 43.6 <0.001
BKK 9.2 8.1 7.8 <0.001
DAK 13.8 13.9 14.8 0.247
TK 5.2 5.3 5.2 0.953
IKK 3.4 3.6 4.1 0.073
Barmer GEK 15.9 15.5 14.2 0.024
Other 10.9 10.2 10.4 0.045
Prescription in the 12 months preceding the index date, %
Oral bisphosphonatesa 22.9 26.6 20.8 <0.001
Calciumb 36.6 34.7 36.3 <0.001
Vitamin Dc 19.4 14.5 13.9 <0.001
Hormone therapyd 5.2 4.6 5.3 0.001
Pain medicatione 65.6 66.1 66.2 0.533
P values were calculated for denosumab versus pooled i.v. bisphosphonate data
ATC Anatomical Therapeutic Chemical, i.v. intravenous
a ATC class: M05B3
bATC class: A12A
cATC class: A11C2 or A11C3
dATC class: G03
eATC class: N02 or M01A
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denosumab and oral bisphosphonates was also seen in the
sensitivity analyses using grace periods of 30, 90, and
120 days (Table 3). Persistence rates for oral
bisphosphonates using these alternative grace periods were
consistently lowest for ibandronate (7.3, 21.2, and 25.1 %)
and highest for risedronate (10.2, 22.6, and 26.9 %) after
2 years of treatment (Table 3).
Cox regression analysis
The multivariate HRs from the Cox regression model are pre-
sented in Tables 4 and 5. Compared with patients receiving
denosumab, those receiving i.v. ibandronate or i.v. zoledronic
acid had a significantly higher risk of discontinuing treatment
(HR=1.65 and 1.28, respectively; both P<0.001; Table 4).
Patients treated with oral bisphosphonates showed an approx-
imately twofold increased risk of treatment discontinuation
compared with those receiving denosumab (HR=2.02 for
oral alendronate, 2.02 for oral ibandronate, and 1.96 for oral
risedronate; all P<0.0001; Table 5).
Patients older than 60 years were significantly less likely to
discontinue osteoporosis treatment than those aged 60 years or
younger (Tables 4 and 5). Patients treated by specialists other
than orthopedic surgeons and internists had a significantly
higher risk of discontinuation than those who obtained their
prescriptions from internists (Tables 4 and 5). However, these
data should be interpreted with caution as the number of pa-
tients treated by other specialists was very low (Tables 1 and 2).
The use of other osteoporosis treatments before the index date,
such as oral bisphosphonates, calcium, or vitamin D, was






150 mg (n = 6235)
Risedronate
35 mg (n= 18,089)
P value
Age ≤60 years, % 7.1 9.9 9.8 8.7 <0.001
Age 61–70 years, % 18.9 19.3 22.0 19.7 <0.001
Age >70 years, % 74.1 70.9 68.2 71.6 <0.001
Specialty of doctor initiating
therapy, %
Orthopedic surgeon 59.9 38.1 42.9 48.6 <0.001
Internist 33.5 56.9 49.4 46.5 <0.001
Other 6.5 5.0 7.7 4.9 <0.001
Health insurance
company, %
AOK 41.6 47.1 44.8 48.1 <0.001
BKK 9.2 9.3 7.9 8.0 <0.001
DAK 13.8 11.9 12.3 11.4 <0.001
TK 5.2 4.5 5.8 4.3 <0.001
IKK 3.4 3.4 4.2 3.5 0.013
Barmer GEK 15.9 12.8 15.2 13.9 <0.001
Other 10.9 11.0 9.8 10.8 0.0365
Prescription in the 12 months
preceding the index date, %
Oral bisphosphonatesa 22.9 4.2 16.9 11.7 <0.001
Calciumb 36.6 31.3 33.2 40.9 <0.001
Vitamin Dc 19.4 10.4 12.1 13.8 <0.001
Hormone therapyd 5.2 3.6 5.0 4.2 <0.001
Pain medicatione 65.6 70.7 66.1 67.3 <0.001
P values were calculated for denosumab versus pooled oral bisphosphonate data
ATC Anatomical Therapeutic Chemical
a ATC class: M05B3
bATC class: A12A
cATC class: A11C2 or A11C3
dATC class: G03
eATC class: N02 or M01A
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associated with a significantly decreased risk of treatment dis-
continuation. While patients receiving analgesics before the
index date were significantly more likely to discontinue therapy
than those who were not receiving pain medication, the effect
was relatively small (HR= 1.08 for i.v. bisphosphonate/
denosumab therapy and 1.02 for oral bisphosphonate/
denosumab therapy). Having health insurance with BKK,
TK, IKK, or Barmer GEK was associated with a lower risk
of treatment discontinuation than having insurance with AOK
(Tables 4 and 5).
Discussion
To our knowledge, this is the first study to assess persistence
rates simultaneously for oral and i.v. bisphosphonates and s.c.
denosumab in a large, real-world population with 2 years of
follow-up. Our data show that patients receiving i.v.
bisphosphonates are significantly more likely to discontinue
treatment than those receiving denosumab (HR=1.28 for zo-
ledronic acid and 1.65 for ibandronate, both P<0.0001) and
those receiving oral bisphosphonates are twice as likely to
discontinue treatment than those receiving denosumab
(HR=1.96–2.02, all P<0.0001). Two-year persistence with
denosumab (39.8 %) was 1.5–2 times higher than with either
i.v. bisphosphonates (20.9–24.8 %) or oral bisphosphonates
(16.7–17.5 %).
Reports on short-term persistence with denosumab have
been published previously [18, 23–25]. Our study found 12-
month persistence with denosumab to be 55.9 %, which was
lower than rates reported in three RCTs: 90.5 % in the
Denosumab Adherence Preference Satisfaction (DAPS)
study, 94 % in the Study of Transitioning from Alendronate
to Denosumab (STAND), and 93 % in the Determining
Efficacy: Comparison of Initiating Denosumab versus
Alendronate (DECIDE) study [24–26]. There is no clear
basis suggesting that this reflects a general trend for poor
persistence with medication in Germany compared with
other countries; indeed, it has been suggested that adhe-
rence to osteoporosis treatment is generally higher in
Europe than in North America [14]. The differences can
be largely attributed to the different study designs. For
example, in the DAPS study [24], persistence with
denosumab was defined as receiving two injections and
completing the treatment period within the study-defined
time span. Moreover, the retrospective, non-interventional
design of our study reflects real-world practice, whereas
patients in RCTs are likely to show good medication-
taking behavior because of regular on-study visits to their
physician and the study eligibility criteria, which exclude
women who have previously received osteoporosis treat-
ments (e.g., DAPS) or restrict the previous treatments per-
mitted (e.g., STAND and DECIDE). In addition, in RCTs,
both patients and physicians must actively agree to partici-
pate, which could lead to selection bias.
Of the different grace periods considered in our sensi-
tivity analyses, the results of the analysis using a 120-day
grace period (which resulted in a 12-month persistence
rate of 65.1 % for denosumab) were closest to, though
still markedly lower than, the reported rates of 82 and
Table 3 Persistence over
12 months and 2 years with
denosumab and intravenous
bisphosphonates in Germany










Denosumab, % 55.9 38.0 61.5 65.1
i.v. ibandronate, % 42.9 31.1 48.2 54.4
i.v. zoledronic acid, % 33.8 20.3 39.7 43.7
Oral alendronate, % 30.1 21.5 35.6 39.7
Oral ibandronate, % 30.1 18.4 35.0 39.4
Oral risedronate, % 31.4 22.6 36.9 41.4
2-year persistence
Denosumab, % 39.8 21.6 46.3 50.6
i.v. ibandronate, % 24.8 15.0 30.2 36.7
i.v. zoledronic acid, % 20.9 6.5 29.5 34.1
Oral alendronate, % 17.3 9.7 22.5 26.5
Oral ibandronate, % 16.7 7.3 21.2 25.1
Oral risedronate, % 17.5 10.2 22.6 26.9
i.v. intravenous
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87.0–95.3 % in the prospective observational studies re-
ported by Silverman et al. and Hadji et al., respectively,
both of which used an 8-week grace period [18, 19]. The
inconsistency in reported persistence is probably a result
of alternative endpoint definitions—both Silverman et al.
and Hadji et al. calculated persistence relative to the pre-
vious injection, whereas we calculated it over the total
study period. The inconsistency could also be due to the
prospective nature of these studies, whereby patients were
aware that their medication-taking behavior was being
observed, which in turn could have increased on-study
persistence [27].
Before this study, data on 2-year persistence with osteopo-
rosis treatments were sparse. In the present analysis, 2-year
persistence was higher for patients receiving denosumab than
for those receiving i.v. or oral bisphosphonates. This result
was seen consistently across different grace periods used in
sensitivity analyses, indicating that the results are robust.
Furthermore, the regression analysis, which was based on
the 60-day grace period, found that the difference in persis-
tence between denosumab and the other agents was statistical-
ly significant.
While 2-year persistence was relatively low with all
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Fig. 1 After 2 years of follow-up,
persistence with denosumab was
significantly higher than with
intravenous (a) or oral (b)
bisphosphonates. Graphs show
Kaplan–Meier curves and 95 %
confidence intervals
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other studies of persistence with bisphosphonates. In the
GRAND study [9], 1- and 2-year persistence with oral
bisphosphonates was 27.9 and 12.9 %, respectively. The
authors of this study discussed the influences of indi-
vidual factors on non-persistence and concluded that the
main drivers of discontinuation are gastrointestinal side
effects and difficulties in taking oral bisphosphonates
(e.g., the need to take them on an empty stomach with
water and then remain upright for at least 30 min [28]).
In a Hungarian cohort study, 1- and 2-year persistence
rates were lower for oral therapies than for parenteral
therapies [15]. Furthermore, a study of osteoporosis
treatment in France found that short dosing intervals
appeared to have a negative effect on treatment compli-
ance and persistence with oral bisphosphonates [29].
Similarly, data from prospective randomized trials have
shown that patients prefer less frequent dosing, such as
6-monthly s.c. injections or 12-monthly i.v. infusions of
denosumab and zoledronic acid, respectively, compared
with once-weekly oral alendronate therapy [30, 31]. In
addition, Palacios et al. [21] evaluated changes in treat-
ment satisfaction among postmenopausal women who
were non-adherent to daily or weekly bisphosphonates
and who were transitioned to either a monthly oral bis-
phosphonate or denosumab; treatment satisfaction was
greater in the denosumab cohort than in the monthly
oral bisphosphonate cohort. Treatment satisfaction with
osteoporosis agents appears to be a decisive parameter
for adherence and persistence [32], which may explain
the results seen in our study. It is also worth consider-
ing the relative longevity of the skeletal effects of
bisphosphonates after treatment discontinuation com-
pared with those of denosumab [33]. This reinforces
the part icular requirement for persistence with
denosumab; recognition of this may influence the em-
phasis with which physicians communicate the impor-
tance of medication adherence to their patients.
Although data on longer-term persistence with i.v.
bisphosphonates are lacking, we are able to compare
the 12-month rates in our study (42.9 and 33.8 % for
i.v. ibandronate and zoledronic acid, respectively) with
those seen in other studies of treatment persistence. For
example, two studies of i.v. zoledronic acid in women
with osteoporosis reported similar persistence rates of
36 and 68 % after 12 months [34, 35]. Additionally, a
population-based study using the IMS database in
Germany demonstrated that 56.6 and 65.6 % of the
study population receiving i.v. ibandronate and zoledro-
nic acid, respectively, were still on treatment after
12 months of follow-up [16]. The findings from our
Table 4 Association of risk of
discontinuation of denosumab or
intravenous bisphosphonate
treatment within 2 years with
predefined outcome variables
(Cox regression model analyses)
Variable Hazard ratio (95 % CI) P value
Ibandronatea 1.65 (1.61–1.69) <0.0001
Zoledronic acida 1.28 (1.23–1.33) <0.0001
Age 61–70 yearsb 0.95 (0.92–0.98) 0.0002
Other doctor specialty (other than orthopedic surgeon or internist)c 1.14 (1.09–1.20) <0.0001
Health insurance company
BKKd 0.93 (0.89–0.96) 0.0002
TKd 0.94 (0.89–0.99) 0.0111
IKKd 0.89 (0.84–0.95) 0.0002
Barmer GEKd 0.94 (0.91–0.97) <0.0001
Previous osteoporosis medication
Oral bisphosphonatese 0.86 (0.84–0.88) <0.0001
Calciumf 0.94 (0.92–0.97) <0.0001
Previous pain medicationg 1.08 (1.06–1.11) <0.0001
Table shows only variables significantly associated with risk of discontinuation
ATC Anatomical Therapeutic Chemical, CI confidence interval
a Reference group = denosumab
b Reference group = age ≤60 years
c Reference group = internist
d Reference group =AOK
eReference group = no previous oral bisphosphonates (ATC class: M05B3)
f Reference group = no previous calcium (ATC class: A12A)
g Reference group = no previous pain medication (ATC class: N02 or M01A)
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study suggest that there is also a high rate of discontin-
uation during the second year of treatment, with persis-
tence rates after 2 years of treatment of 24.8 and
21.2 % for i.v. ibandronate and i.v. zoledronic acid,
respectively.
Several studies have found associations between poor
persistence with osteoporosis treatment and fracture risk
[9, 14, 36–39]; hence, the low rates of persistence seen
in the current study are of concern, and it is important
to gain a better understanding of how we can optimize
medication-taking behavior. This, in turn, could allow
us to maximize treatment effects, prevent fractures, and
minimize healthcare costs [40].
Little is known about factors associated with treatment dis-
continuation over a 2-year period. We found that being over
60 years of age was associated with a lower risk of treatment
discontinuation compared with younger individuals. This ob-
servation might be due to older patients having more severe
disease than younger patients and therefore being more likely
to be prescribed denosumab or i.v. bisphosphonates, which are
associated with higher long-term persistence rates than the
oral bisphosphonates typically used as first-line treatment.
We also found that previous treatment with bisphosphonates,
calcium, vitamin D, or pain medication was associated with
better persistence. This is in line with previously published
studies of determinants of persistence with denosumab [17,
18] and could reflect a tendency for women who have previ-
ously received osteoporosis treatment to be better informed
about their disease and to receive more information from their
prescriber than treatment-naïve women [17]. In this study,
patients insured through AOK demonstrated poorer persis-
tence than patients insured through BKK, TK, IKK, or
Barmer GEK. AOK is the largest statutory health insurance
provider in Germany, so the low persistence in patients in this
group is of concern. It may, however, reflect a higher propor-
tion of patients with low income, or who are unemployed or
retired, among the AOK population compared with other in-
surance groups. Indeed, a previous study found that income
level was significantly associated with persistence in patients
with osteoporosis [41].
Certain limitations warrant consideration. The retro-
spective nature of the study, as well as the limited number
of factors potentially associated with persistence for
which data are included in the database, prevents us from
Table 5 Association of risk of
discontinuation of denosumab or
oral bisphosphonate treatment
within 2 years with predefined
outcome variables (Cox
regression model analyses)
Variable Hazard ratio (95 % CI) P value
Alendronate 70 mga 2.02 (1.98–2.06) <0.0001
Ibandronate 150 mga 2.02 (1.95–2.09) <0.0001
Risedronate 35 mga 1.96 (1.91–2.01) <0.0001
Age
Age 61–70 yearsb 0.91 (0.89–0.93) <0.0001
Age >70 yearsb 0.89 (0.88–0.91) <0.0001
Other doctor specialty (other than orthopedic surgeon or internist)c 1.22 (1.19–1.26) <0.0001
Health insurance company
BKKd 0.95 (0.93–0.97) <0.0001
IKKd 0.88 (0.85–0.91) <0.0001
Barmer GEKd 0.96 (0.94–0.97) <0.0001
Previous osteoporosis medication
Oral bisphosphonatese 0.90 (0.88–0.92) <0.0001
Calciumf 0.93 (0.92–0.95) <0.0001
Vitamin Dg 0.96 (0.95–0.98) <0.0001
Previous pain medicationh 1.02 (1.00–1.03) 0.016
Table shows only variables significantly associated with risk of discontinuation
ATC Anatomical Therapeutic Chemical, CI confidence interval
a Reference group = denosumab
b Reference group = age ≤60 years
c Reference group = internist
d Reference group =AOK
eReference group = no previous oral bisphosphonates (ATC class: M05B3)
f Reference group = no previous calcium (ATC class: A12A)
g Reference group = no previous vitamin D (ATC class: A11C2 or A11C3)
h Reference group = no previous pain medication (ATC class: N02 or M01A)
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identifying further risk factors for poor persistence. Also,
associations with possible confounders, such as severity
of disease, bone mineral density, bone turnover markers,
and prevalent fractures, could not be assessed. Physicians
may vary in the way they classify new versus continued
use of osteoporosis treatments. In particular, re-initiation
of previous treatment may not be coded consistently. The
data may also be affected by confounding by indication,
because patients who receive injectable agents are more
likely to have severe disease and to have received previ-
ous therapy than those receiving oral bisphosphonates.
Individuals who discontinued their original therapy and
started another drug within 60 days were included in the
drug cohort in which they maintained the longest duration
of persistence, which may have led to an overestimation
of persistence for the agents used as the initial therapy in
such cases. Analysis of persistence may also have been
confounded by instances of extended prescription inter-
vals, undetected by the maximum grace period of
120 days. For example, data demonstrating that the bene-
fits of a single i.v. dose of zoledronic acid endure for
more than a year may underlie a trend for biennial dosing
in some regions [42]. This is not recognized practice in
Germany, however, and is not advocated by treatment
guidelines; thus, it is unlikely to have affected our find-
ings significantly [43]. Finally, this analysis may have
been complemented by the availability of additional data
that were not analyzed, such as further details on previous
fractures, osteoporosis treatment history, and comorbidity
profiles of patients, as well as a more comprehensive
breakdown of physician specialty. It would be of interest
to examine the effects of these variables in future studies.
Our study has several strengths. Our analysis used real-
world data from physicians, capturing over 60 % of prescrip-
tions for osteoporosis treatment in women and providing in-
sights into treatment persistence in a real-world clinical prac-
tice setting. Furthermore, we assessed treatment persistence
using four different grace periods and showed that shorter
gaps (e.g., 30 days) might underestimate persistence whereas
longer gaps might overestimate persistence. Finally, unlike
previous studies, we compared all available bisphosphonate
treatment regimens, as well as denosumab, for a long duration
(>12 months) of follow-up.
Conclusion
Two-year persistence was 1.5–2 times higher with denosumab
than with bisphosphonates, and the risk of discontinuing treat-
ment was significantly lower with denosumab than with
bisphosphonates, even if patients were receiving i.v.
ibandronate or i.v. zoledronic acid. Although this improve-
ment has value, further increases in persistence with
antiresorptive agents in patients with osteoporosis are needed.
Greater understanding of the factors associated with poor per-
sistence is required in order to improve medication-taking
behavior in patients at high risk of treatment discontinuation
and to maximize fracture risk reduction.
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